Use of Bacillus coagulans BC07 in preparing immune function enhancing food and / or immunomodulatory medicine and / or antibacterial agent

By developing the Bacillus BC07 strain with excellent performance, the problem of limited use of the existing strain was solved, and the immune function and antibacterial effect were enhanced, the number of immune cells and cytokine content was significantly improved, and the intestinal microbial structure was regulated. It also effectively inhibits a variety of pathogens and expands its application in food, drugs and antibacterial agents.

CN118383523BActive Publication Date: 2024-11-12JIANGSU WECARE BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410831286.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-06-25
Publication Date
2024-11-12
Estimated Expiration
2044-06-25

AI Technical Summary

Technical Problem

Existing Bacillus strains have limited uses in enhancing immunity and antibacterial, and lack diverse options in the market to meet industrial production and consumer needs, especially in anti-pathogenic bacteria.

Method used

Develop and utilize the Bacillus BC07 strain with excellent performance to prepare foods to enhance immune function, immunomodulatory drugs and antibacterial agents by proliferating immune cells, regulating intestinal flora, and inhibiting pathogens, including the proliferation and escalation of RAW264.7 cells. High thymus and spleen index, increase cytokine content, regulate intestinal flora abundance and inhibit enterotoxin production and other pathogenic bacteria.

Benefits of technology

It significantly enhances immune function, improves the number of immune cells and cytokine content of immune-lower mice, regulates the structure of intestinal flora, significantly inhibits a variety of pathogenic bacteria, and expands the antibacterial spectrum and immune regulation purposes of BC07 strain.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118383523B_ABST
    Figure CN118383523B_ABST
Patent Text Reader

Abstract

The use of Bacillus coagulans BC07 in the preparation of foods for enhancing immune function and / or immunomodulatory drugs and / or antibacterial agents of the present invention belongs to the field of microbial technology. The present invention provides the use of Bacillus coagulans BC07 in the preparation of foods for enhancing immune function and / or immunomodulatory drugs and / or antibacterial agents, and the antibacterial spectrum of the antibacterial agent includes: enterotoxigenic Escherichia coli, Yersinia enterocolitica, Streptococcus anginosus, Enterobacter sakazakii, and Escherichia fergusonii. The BC07 strain can enhance immune function and immunomodulation by proliferating immune cells, increasing thymus index, increasing spleen index, increasing cytokine content, reducing ileal tissue damage, and regulating intestinal flora. At the same time, BC07 has a good inhibitory effect on pathogens such as enterotoxigenic Escherichia coli, Yersinia enterocolitica, Streptococcus anginosus, Enterobacter sakazakii, and Escherichia fergusonii.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of microorganisms, and particularly relates to use of Bacillus coagulans BC07 in preparing immune function enhancing foods and / or immune regulating drugs and / or antibacterial agents. Background Art

[0002] Immunomodulation is an important system for the body to maintain physiological balance and stability, and to maintain health and vitality. It is based on the stable operation of the immune system and is the result of the joint influence of immune cells and immune molecules. Immune disorders produce a variety of diseases and endanger human health. Cyclophosphamide, as a drug for the treatment of cancer and other diseases, has important effects, but it has damaging side effects on organs such as the intestines, causing digestive tract diseases and subsequently causing low immunity. Previous studies have shown that dietary intervention has a profound effect on human immune regulation, improving the host's intestinal function, creating a good intestinal homeostasis, and preventing low immunity.

[0003] Probiotics are defined as "live microorganisms that, when ingested in sufficient quantities, are beneficial to the health of the host." They are tolerant to gastric acid and bile in the gastrointestinal tract, can colonize in the intestines, and enhance the host's immune system. Probiotics regulate the innate and acquired immune systems and then activate the mucosal system and systemic immune responses to achieve the effect of immunoregulation. Therefore, it is a very good strategy to regulate the intestinal flora by supplementing probiotics and strengthen immune regulation at the same time.

[0004] Bacillus coagulans ( Bacillus coagulans ) is a lactic acid bacterium that produces spores during the fermentation process. The Bacillus coagulans currently available on the market cannot meet the multiple selection needs of industrial production, market and consumers, and there is little room for choice. Especially in terms of enhancing immunity, the existing technology in this field provides fewer Bacillus coagulans strains. Therefore, this field still needs to develop more beneficial new strains of Bacillus coagulans.

[0005] Strain BC07 is a strain of Bacillus coagulans with excellent performance recorded in Chinese invention patent 202211141056.X. It has been proven to have good effects in inhibiting pathogens such as enterotoxigenic Escherichia coli (ETEC), enteropathogenic Escherichia coli (EPEC), Shigella flexneri, Salmonella Enteritidis, Clostridium difficile, etc., relieving diarrhea or regulating intestinal flora, but its uses are limited, and it is urgent to develop more beneficial uses for the benefit of society. Summary of the invention

[0006] Based on the above-mentioned needs of the prior art in the art, the present invention provides the use of Bacillus coagulans BC07 in preparing immune function enhancing foods and / or immunomodulatory drugs and / or antibacterial agents.

[0007] The technical solution of the present invention is as follows:

[0008] The use of Bacillus coagulans BC07 in the preparation of immune function enhancing foods and / or immunomodulatory drugs and / or antibacterial agents is characterized in that the antibacterial spectrum of the antibacterial agent includes: enterotoxigenic Escherichia coli, Yersinia enterocolitica, Streptococcus anginosus, Enterobacter sakazakii, and Escherichia ferguson.

[0009] The immunity enhancement or immune regulation includes: proliferating immune cells, increasing thymus index, increasing spleen index, increasing cytokine content, reducing ileum tissue damage, and regulating intestinal flora.

[0010] The immune cells refer to RAW264.7 cells.

[0011] The cytokines include: IL-6, IL-10, IL-17, IL-1β, and TNF-α.

[0012] Regulating the intestinal flora includes: increasing the richness of the intestinal flora, improving the ACE index and Chao 1 index.

[0013] Regulating the intestinal flora also includes: increasing the abundance of Lactobacillus, Lachnospiraceae_NK4A136_group, and Clostridium_UCG_014_unclassified bacteria, and reducing the abundance of Desulfovibrio, unclassified Desulfovibrio, and unclassified Eubacterium copropertin-producing group.

[0014] The immune function enhancing food comprises functional active ingredients; the functional active ingredients comprise Bacillus coagulans BC07;

[0015] Preferably, the food for enhancing immune function further comprises: auxiliary materials.

[0016] The immunomodulatory drug includes a pharmacologically active ingredient; the pharmacologically active ingredient includes Bacillus coagulans BC07;

[0017] Preferably, the immunomodulatory drug further comprises: pharmaceutically acceptable excipients.

[0018] The antibacterial agent includes an antibacterial active ingredient; the antibacterial active ingredient includes Bacillus coagulans BC07;

[0019] Preferably, the antibacterial agent further comprises: an adjuvant.

[0020] The deposit number of the Bacillus coagulans BC07 is CCTCCNO: M2022195.

[0021] The beneficial effects of the present invention are as follows:

[0022] The present invention has excavated the Bacillus coagulans with the deposit number of CCTCCNO: M2022195 ( Bacillus coagulans)BC07 has excellent uses in immune regulation, and further expanded the antibacterial effect of BC07 strain. Experiments have shown that BC07 strain can enhance immune function and immune regulation by proliferating immune cells, increasing thymus index, increasing spleen index, increasing cytokine content, reducing ileal tissue damage, and regulating intestinal flora. The proliferation rate of BC07 strain on RAW264.7 cells is as high as 137.46%, which can increase the content of cytokines such as IL-6, IL-10, IL-17, IL-1β, TNF-α in the serum of immunocompromised mice, significantly increase the abundance of Lactobacillus, Lachnospiraceae_NK4A136_group, Clostridium_UCG_014_unclassified bacteria, and significantly reduce the abundance of Desulfovibrio, unclassified Desulfovibrio, and unclassified Eubacterium coprosterol-producing group. At the same time, the BC07 strain has a good inhibitory effect on pathogenic bacteria such as enterotoxigenic Escherichia coli, Yersinia enterocolitica, Streptococcus anginosus, Enterobacter sakazakii, and Escherichia fergusonii. The deposit information of the BC07 strain of the present invention is as follows:

[0023] Deposit number: CCTCC NO: M 2022195;

[0024] Category naming: Bacillus coagulans BC07;

[0025] Deposit date: March 4, 2022;

[0026] Depository: China Center for Type Culture Collection;

[0027] Deposit address: Wuhan University, Wuhan, China. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 This is a line graph showing the effect of Bacillus coagulans BC07 on the body weight of immunocompromised mice in Experimental Example 5 of the present invention.

[0029] Figure 2 This is a bar graph of the effects of Bacillus coagulans BC07 on immune organs of immunocompromised mice in Experimental Example 5 of the present invention, A is a bar graph of the thymus index, and B is a bar graph of the spleen index.

[0030] Figure 3 This is a bar graph showing the effects of Bacillus coagulans BC07 on the serum immune factors of immunocompromised mice in Experimental Example 6 of the present invention.

[0031] Figure 4 This is a pathological section diagram of the effect of Bacillus coagulans BC07 on the ileum tissue of immunocompromised mice in Experimental Example 7 of the present invention.

[0032] Figure 5 This is a bar graph of the α-diversity analysis results of the intestinal flora of each group of mice in Experimental Example 8 of the present invention.

[0033] Figure 6 This is a graph showing the β-diversity analysis results of the intestinal flora of each group of mice in Experimental Example 8 of the present invention.

[0034] Figure 7 This is a bar graph of the species diversity analysis results of the intestinal flora of each group of mice in Experimental Example 8 of the present invention at the genus level.

[0035] Figure 8 This is a graph showing the OTUs clustering analysis results of the intestinal flora of each group of mice in Experimental Example 8 of the present invention. DETAILED DESCRIPTION

[0036] The present invention is further described in detail below in conjunction with the accompanying drawings, embodiments and experimental examples, but the embodiments of the present invention are not limited thereto, nor are they intended to limit the scope of protection of the present invention.

[0037] 1. Sources of biological materials

[0038] (A) The RAW264.7 cells used in Experimental Example 3 of the present invention are commercially available.

[0039] (ii) The enterotoxigenic Escherichia coli, Enterobacter sakazakii, and Yersinia enterocolitica used in Experimental Example 4 of the present invention were purchased from Guangdong Microbiological Culture Collection Center.

[0040] (III) The Streptococcus anginosus and Escherichia fergusonii used in Experimental Example 4 of the present invention have been registered in NCBI with the registration numbers MW090399 and MT516163, respectively.

[0041] (IV) BALB / c male mice (18-20 g) used in Experimental Examples 5, 6, 7, and 8 of the present invention were purchased from Beijing Sibeifu Biotechnology Co., Ltd.

[0042] 2. Culture medium used in the experimental examples of the present invention: (i) MRS solid culture medium: peptone 10g, beef extract 10g, yeast extract 5g, diammonium citrate 2g, glucose 20g, Tween 80 1mL, sodium acetate 5g, dipotassium phosphate 2g, magnesium sulfate 0.58g, manganese sulfate 0.25g, agar 15g, distilled water 1000mL, sterilized at 121℃ for 20min, pH adjusted to 6.8. (ii) MRS liquid culture medium: peptone 10g, beef extract 10g, yeast extract 5g, diammonium citrate 2g, glucose 20g, Tween 80 1mL, sodium acetate 5g, dipotassium phosphate 2g, magnesium sulfate 0.58g, manganese sulfate 0.25g, distilled water 1000mL, sterilized at 121℃ for 20min, pH adjusted to 6.8.

[0043] Unless otherwise specified, the experimental examples of the present invention and various reagents and consumables used in the experimental examples are commercially available, and the relevant experimental steps are common operations in the art and have technical meanings that can be conventionally understood by those skilled in the art.

[0044] The present invention provides the use of Bacillus coagulans BC07 in preparing immune function enhancing food and / or immunomodulatory drugs and / or antibacterial agents. All embodiments of the present invention have the following common features: the antibacterial spectrum of the antibacterial agent includes: enterotoxigenic Escherichia coli, Yersinia enterocolitica, Streptococcus anginosus, Enterobacter sakazakii, and Escherichia fergusonii.

[0045] In a specific embodiment, the immunity enhancement or the immune regulation includes: proliferating immune cells, increasing thymus index, increasing spleen index, increasing cytokine content, reducing ileal tissue damage, and regulating intestinal flora.

[0046] In a more specific embodiment, the immune cell is a RAW264.7 cell.

[0047] In some embodiments, the cytokines include: IL-6, IL-10, IL-17, IL-1β, TNF-α.

[0048] In other embodiments, regulating the intestinal flora includes: increasing the richness of the intestinal flora, improving the ACE index and the Chao 1 index.

[0049] In a further embodiment, regulating the intestinal flora also includes: increasing the abundance of Lactobacillus, Lachnospiraceae_NK4A136_group, Clostridium_UCG_014_unclassified bacteria, and reducing the abundance of Desulfovibrio, unclassified Desulfovibrio, and unclassified Eubacterium copropergen-producing group.

[0050] In a specific embodiment, the immune function enhancing food comprises functional active ingredients; the functional active ingredients comprise Bacillus coagulans BC07;

[0051] Preferably, the food for enhancing immune function further comprises: auxiliary materials.

[0052] In a more specific embodiment, the excipient is selected from: solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculating agents, filter aids, release retardants, etc.

[0053] According to the contents of the present invention, for different needs in actual production applications, combined with conventional technical means in the field of drug preparation (for example, "Encyclopedia of Preparation Technology", "Drug Preparation Technology", "Research and Application of Microbial Agent Technology", etc.), those skilled in the art can select and formulate the above-mentioned excipients, and make Bacillus coagulans BC07 with a preservation number of CCTCCNO: M2022195 into different dosage forms, such as powders, tablets, injections, oral liquids, suppositories, gels, patches, sprays, lotions, granules, etc.

[0054] In a specific embodiment, the dosage form of the product is selected from: one or more of powder, tablet, liquid, and capsule.

[0055] In some specific embodiments, the immunomodulatory drug includes a pharmacologically active ingredient; the pharmacologically active ingredient includes Bacillus coagulans BC07;

[0056] Preferably, the immunomodulatory drug further comprises: pharmaceutically acceptable excipients.

[0057] In a more specific embodiment, the pharmaceutically acceptable excipient is selected from: solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculating agents, filter aids, release retardants, etc.

[0058] According to the contents of the present invention, for different needs in actual production applications, combined with conventional technical means in the field of drug preparation (for example, "Encyclopedia of Preparation Technology", "Drug Preparation Technology", "Research and Application of Microbial Agent Technology", etc.), those skilled in the art can select and formulate the above-mentioned pharmaceutically acceptable excipients, and prepare Bacillus coagulans BC07 with a preservation number of CCTCCNO: M2022195 into different dosage forms, such as powders, tablets, injections, oral liquids, suppositories, gels, patches, sprays, granules, etc.

[0059] In a specific embodiment, the dosage form of the drug is selected from: one or more of powder, tablet, liquid, and capsule.

[0060] In other specific embodiments, the antibacterial agent includes an antibacterial active ingredient; the antibacterial active ingredient includes Bacillus coagulans BC07;

[0061] Preferably, the antibacterial agent further comprises: an adjuvant.

[0062] In a specific embodiment, the deposit number of the Bacillus coagulans BC07 is CCTCCNO: M2022195.

[0063] Experimental Example 1: Isolation and Identification of Bacillus coagulans BC07

[0064] (1) Strain isolation

[0065] Take a kimchi sample and put it into a centrifuge tube filled with sterile physiological saline, shake it to mix it thoroughly, let it stand, take 2 ml of the sample suspension and place it in an 80°C water bath for 10 minutes, perform a 10-fold gradient dilution, and then select a suitable dilution gradient to spread on an MRS agar medium containing 1.5% calcium carbonate, and place it in a 42°C incubator for constant temperature culture for 72 hours. After the colonies grow out, select white, shiny, round, neatly edged, slightly convex, and large transparent circle single colonies, perform Gram staining, observe cell morphology, and then select single colonies to repeatedly streak on a solid plate of Bacillus coagulans for purification to obtain a pure culture strain.

[0066] (2) Strain identification

[0067] Morphological characteristics: The purified Bacillus coagulans is round on the solid plate culture medium, with a colony diameter of 2 to 5 mm, off-white, with neat edges and a moist surface; Gram staining microscopic examination shows the bacteria as purple, single rod or double rod, and one end swells and becomes drumstick-shaped when spores are formed, which is a unique feature of Bacillus coagulans.

[0068] 16SrDNA identification: The strain was PCR amplified using the universal primers described in CN114574405A. After the PCR product was detected by gel electrophoresis, it was sent to Wuhan Jinkairui Biotechnology Co., Ltd. for sequencing. The measured gene sequence was submitted to the NCBI database for BLAST analysis and comparison, with the 16SrRNA gene sequence homology ≥99% as the identification standard. The identification results showed that the strain belonged to Bacillus coagulans, and the strain was named BC07 and sent for preservation. Its preservation information is as follows:

[0069] Deposit number: CCTCCNO: M2022195;

[0070] Category naming: Bacillus coagulans ;

[0071] Deposit date: March 4, 2022;

[0072] Depository: China Center for Type Culture Collection;

[0073] Deposit address: Wuhan University, Wuhan, China.

[0074] Experimental Example 2: Tolerance test of Bacillus coagulans BC07 to artificial gastric juice and artificial intestinal juice

[0075] (1) Preparation of simulated artificial gastric juice: prepare 0.5% NaCl solution, add 0.3% pepsin, adjust the pH to 3.5 with 1 mol / L HCl, and then filter and sterilize with a 0.22 μm microporous filter membrane after fully dissolving.

[0076] (2) Simulated artificial intestinal fluid: prepare PBS solution, add 0.1% trypsin and then 0.3% ox bile salt, adjust the pH value to 8.0 with 0.1 mol / L NaOH, fully dissolve the ingredients and filter with a 0.22 μm microporous filter to sterilize for later use.

[0077] (3) Tolerance test:

[0078] Take 1 mL of spore suspension of Bacillus coagulans BC07, centrifuge at 6000 rpm for 6 min, discard the supernatant, add PBS to shake evenly, centrifuge at 10000 rpm for 2 min, carefully discard the supernatant to collect the bacteria. Then add 1 mL of simulated gastric juice and artificial intestinal juice, incubate at 37 ° C for 3 h, centrifuge the treated solution after the incubation, and determine the total number of viable bacteria (CFU / mL) by dilution plate method.

[0079] Survival rate% = (3h live bacteria count / 0h live bacteria count) × 100%

[0080] Table 1. BC07 artificial gastric juice and artificial intestinal juice tolerance test data

[0081]

[0082] The results in Table 1 above show that the survival rate of Bacillus coagulans BC07 in pH 3.5 artificial gastric juice is 100%, and the survival rate in 0.3% artificial bile salt solution is 99%, indicating that Bacillus coagulans BC07 has strong gastrointestinal tolerance.

[0083] Experimental Example 3: Effect of Bacillus coagulans BC07 on the proliferation ability of RAW264.7 cells

[0084] RAW264.7 cells were collected at 1×10 5The cells were inoculated at a density of 100 μL / mL in a 96-well cell culture plate and cultured for 24 hours. After the cells adhered to the wall, the DMEM cell culture medium with bacteria was added to replace the original culture medium. The experiment set up a blank group (DMEM culture medium) and a probiotic group (the culture medium with good live bacteria was washed twice with PBS and resuspended with DMEM), and each group was set up with 5 replicates. Cultured in a 37℃, 5% CO2 incubator for 24 hours. After the culture was completed, the old culture medium was aspirated, and 100 μL of DMEM culture medium containing 10% CCK-8 was added to each well, protected from light, and placed in a CO2 incubator for further culture for 2 hours; the OD value of each well was detected at 450nm, and the relative cell proliferation rate was calculated according to the following formula.

[0085] Relative cell proliferation rate% = OD value of experimental group / OD value of blank group

[0086] The experimental results showed that the proliferation rate of RAW264.7 cells by Bacillus coagulans BC07 was 137.46%, indicating that BC07 has the potential for immunomodulation.

[0087] Experimental Example 4: Inhibitory effect of Bacillus coagulans BC07 on pathogenic bacteria

[0088] (1) Preparation of indicator bacteria suspension

[0089] The indicator strains were activated on LB solid plate medium, cultured at 37°C for 24 h, and the bacterial moss was picked up and placed in physiological saline to prepare a bacterial suspension for 10 8 After culturing Streptococcus anginosus in TSA solid blood plate medium containing 5% defibrinated sheep blood at 37°C for 24 h, the concentration of bacterial suspension was adjusted to 10 8 CFU / mL.

[0090] (2) Preparation of fermentation broth

[0091] Preparation of strain fermentation broth: Bacillus coagulans BC07 was inoculated into liquid MRS culture medium in a certain proportion, and cultured at 42° C. for 24 h to obtain BC07 bacterial liquid.

[0092] (3) Antibacterial experiment

[0093] Cool the LB medium containing 1.5% agar (TSA medium containing 5% defibrinated sheep blood for Streptococcus anginosus) to about 55°C and mix it with the indicator bacteria suspension in a certain proportion so that the number of viable indicator bacteria is around 10 6 CFU / mL, and then quickly poured into the plate with the Oxford cup placed in advance. After the culture medium cooled and solidified, take out the Oxford cup and inject 200μL of the strain fermentation liquid (the number of viable bacteria is 10 8 CFU level), and the diameter of the inhibition zone was measured after overnight culture at 37°C.

[0094] Table 2. Antagonistic ability of BC07 against pathogens

[0095] Pathogen name Diameter of inhibition zone (mm) Enterotoxigenic Escherichia coli 20±0.6 Yersinia enterocolitica 18±0.0 Streptococcus anginosus 17.2±0.3 Enterobacter sakazakii 18.3±0.3 Escherichia Ferguson 20.5±0.5

[0096] The experimental results are shown in Table 2, indicating that BC07 has different degrees of antagonism against the above pathogens.

[0097] Experimental Example 5: Effects of Bacillus coagulans BC07 on body weight and immune organs of mice

[0098] Establishment of immunosuppression model in mice:

[0099] Specific pathogen-free BALB / c male mice (18–20 g) were purchased from Beijing Sibeifu Biotechnology Co., Ltd. and housed in the animal room of Hubei Food and Drug Safety Evaluation Center. The temperature was maintained at 22 ± 2 °C, the humidity was 50 ± 5%, the light-dark cycle was 12 h, and free access to water and food was allowed.

[0100] During the whole experiment, mice in the NC and MC groups were gavaged with 0.2 mL of sterile saline every day, and mice in the BC07 group were gavaged with an equal amount of Bacillus coagulans BC07 suspension (the number of viable bacteria was 10 9 CFU / mL). On days 7 to 9 of the experiment, mice in the MC and BC07 groups were continuously injected with cyclophosphamide (CTX, 80 mg / kg / d) for 3 days to establish an immunosuppressive mouse model, and the NC group was injected with an equal volume of sterile saline. The mice were killed on day 15, and samples were collected for subsequent analysis. The detailed animal experiments are shown in Table 3.

[0101] Table 3. Animal experiment design and grouping

[0102] Group Name Group Description NC Group The patients were gavaged with saline for 14 days, and 0.2 mL of saline was injected intraperitoneally on the 7th, 8th, and 9th days. MC Group The patients were gavaged with normal saline for 14 days, and 0.2 mL of cyclophosphamide (80 mg / kg) was injected intraperitoneally on days 7, 8, and 9. BC07 Group <![CDATA[Continuous intragastric administration of viable cells of Bacillus coagulans BC07 (viable cell count is 10 9 CFU / mL, 0.2 mL / day / animal) for 14 days, and intraperitoneal injection of 0.2 mL of cyclophosphamide (80 mg / kg) on days 7, 8, and 9]]>

[0103] After one week of adaptive feeding, the mice were randomly divided into three groups. The body weights of the experimental mice were measured on the 1st, 7th, 10th and 14th days. During the autopsy, the spleen and thymus of the mice were collected, and the thymus index and spleen index of the mice were calculated.

[0104] The calculation formula of immune organ index is as follows:

[0105] Immune organ index = immune organ mass (mg) / body weight (g)

[0106] The weight of mice was recorded on days 1, 7, 10, and 14. The experimental results are shown in Figure 1 As shown in the figure, after three days of continuous injection of CTX, the weight of mice in the MC and BC07 groups decreased, and the weight of mice in the MC group decreased severely. After stopping the administration, the weight of mice in the MC and BC07 groups continued to decrease. On the 14th day, the weight of mice in the BC07 group was significantly higher than that in the MC group, indicating that BC07 significantly inhibited the weight loss of immunocompromised mice induced by cyclophosphamide. Figure 2 It can be seen that compared with the NC group, the thymus and spleen indexes of the mice in the MC group decreased significantly, indicating that the thymus and spleen of the mice in the MC group were atrophied. Compared with the MC group, the thymus and spleen indexes of the mice in the BC07 group increased significantly, indicating that oral administration of BC07 can alleviate cyclophosphamide-induced atrophy of the thymus and spleen in mice.

[0107] Experimental Example 6: Effects of Bacillus coagulans BC07 on serum cytokines in mice

[0108] The mouse blood was collected into a 2 mL centrifuge tube and centrifuged at 4000 rpm / min for 10 minutes. The supernatant was stored in a -20°C refrigerator for subsequent experiments. According to the experimental method of the ELISA kit, the levels of IL-6, IL-10, IL-17, IL-1β, TNF-α, and SIgA in mouse serum were determined. The experimental results are shown in Figure 3 As shown, injection of cyclophosphamide induced a decrease in the SIgA content in the serum of mice. SIgA is the main substance that forms the first barrier of the intestinal mucosal immune system and is also the main effector. Oral administration of BC07 significantly increased the SIgA content in the serum. At the same time, it was found that CTX induced a decrease in the IL-6, IL-10, IL-17, IL-1β, and TNF-α content in the serum of immunosuppressed mice, and oral administration of BC07 could increase the IL-6, IL-10, IL-17, IL-1β, and TNF-α content in the serum.

[0109] Experimental Example 7: Effects of Bacillus coagulans BC07 on mouse ileum tissue

[0110] After killing the mice, 0.5 cm2 of ileum tissue was collected, fixed with 10% formaldehyde solution, and then stained with hematoxylin-eosin (HE). Finally, the intestinal structure was observed using an optical microscope. Figure 4 As shown in the figure, the ileum mucosa of the MC group was severely damaged, the intestinal muscle layer and intestinal glands were missing, the intestinal villi were destroyed and severely reduced, the intestinal tissue structure was incomplete, and inflammatory cell infiltration was visible. Compared with the MC group, the intestinal damage of the mice in the BC07 group was restored, and the intestinal morphology and structure were relatively complete, indicating that Bacillus coagulans BC07 can enhance the intestinal mucosal barrier and reduce ileum tissue damage.

[0111] Experimental Example 8: Effects of Bacillus coagulans BC07 on intestinal flora of mice

[0112] After the experiment, the mice were killed and dissected, and their cecal contents were collected. The 16SrDNA of the cecal contents was sequenced and analyzed.

[0113] (1) α-diversity analysis and β-diversity analysis

[0114] Analysis of α-diversity of mouse intestinal flora showed Figure 5, compared with the control group, the ACE and Chao 1 indices of the intestinal flora of mice in the model group were significantly decreased, indicating that CTX induced intestinal flora disorder in mice and caused a decrease in the diversity of intestinal flora. After feeding BC07, the ACE and Chao 1 indices of the intestinal flora of mice were significantly higher than those in the model group, indicating that BC07 could regulate the intestinal flora and increase the richness of the intestinal flora in immunocompromised mice. β-diversity measures the similarity of the flora composition between different samples, that is, it focuses on the differences in the flora composition between samples. The experimental results are as Figure 6 shown. The MC group was significantly separated from the NC group, indicating that there were significant differences in the microbial composition between the MC group and the NC group. The BC07 group was adjacent to and overlapped with the NC group, indicating that gavage with BC07 made the composition of the microbiota in the intestines of immunocompromised mice tend to be normal.

[0115] (2)Genus-level species diversity analysis

[0116] The changes in the relative abundances at the genus level in the cecal contents of mice among groups were analyzed. The experimental results are as Figure 7 shown. The results showed that the abundances of Ligilactobacillus, Lachnospiraceae_NK4A136_group, and unclassified_Clostridia_UCG_014 in the MC group were lower than those in the NC group. The relative abundances of Desulfovibrio, unclassified_Desulfovibrionaceae, and unclassified_[Eubacterium]_stercobilinigenes_group were significantly increased in the MC group compared with the NC group. Gavage with Bacillus coagulans BC07 could significantly increase the abundances of Ligilactobacillus, Lachnospiraceae_NK4A136_group, and unclassified_Clostridia_UCG_014, and significantly decrease the abundances of Desulfovibrio, unclassified_Desulfovibrionaceae, and unclassified_[Eubacterium]_stercobilinigenes_group.

[0117] (3)OTUs clustering analysis

[0118] The experimental results are as Figure 8 shown. The number of shared OTUs between the MC group and the NC group was 137, and the number of shared OTUs between the LP group and the NC group was 169, indicating that gavage with Bacillus coagulans BC07 could increase the shared flora in the intestines of immunosuppressed mice and normally fed mice.

Claims

1. Use of Bacillus coagulans BC07 in preparing a product for enhancing immune function or immunomodulation, characterized in that: The deposit number of the Bacillus coagulans BC07 is CCTCC NO: M2022195; the product is not a food or health product; The immunity enhancement or immune regulation is: proliferation of immune cells, increase of thymus index, increase of spleen index, increase of cytokine content, reduction of ileum tissue damage, and regulation of intestinal flora; The immune cells refer to RAW264.7 cells; The cytokines are: IL-6, IL-10, IL-17, IL-1β, TNF-α; The intestinal flora regulation includes: increasing the richness of the intestinal flora, and improving the ACE index and the Chao 1 index.

2. Use of Bacillus coagulans BC07 in the preparation of an antibacterial agent, characterized in that: The deposit number of the Bacillus coagulans BC07 is CCTCC NO: M2022195; the antibacterial spectrum of the antibacterial agent is: enterotoxigenic Escherichia coli, Yersinia enterocolitica, Streptococcus anginosus, Enterobacter sakazakii, and Escherichia fergusonii.

3. The use of Bacillus coagulans BC07 according to claim 1 in preparing a product for enhancing immune function or immunomodulation, characterized in that: Regulating the intestinal flora also includes: increasing the abundance of Lactobacillus, Lachnospiraceae_NK4A136_group, and Clostridium_UCG_014_unclassified bacteria, and reducing the abundance of Desulfovibrio, unclassified Desulfovibrio, and unclassified Eubacterium copropertin-producing group.

4. Use of Bacillus coagulans BC07 according to claim 1 or 3 in preparing products for enhancing immune function or immunomodulation, characterized in that: The immune function enhancement or immunomodulation product also includes: auxiliary materials.

5. Use of Bacillus coagulans BC07 in preparing an antibacterial agent according to claim 2, characterized in that: The antibacterial agent also includes: an adjuvant.